Glaucoma
Conditions
Interventions
Tafluprost monotherapy of 12weeks, Latanoprost monotherapy of 12weeks and if possible, continue monotherapy with either ophthalmic solution for 52weeks
Latanoprost monotherapy of 12weeks, Taflupros
Sponsors
Department of ophthalmology, Kyoto Prefectural University of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Diagnosed with normal-tension glaucoma 2. Person whose agreement is shown by him/herself 3. Over 20 years old on the date of agreement. 4. Both male and female 5. Outpatient treatment 6. Having latanoprost monotherapy treatment more than 4 weeks and whose intraocular pressure is between 10 mmHg and 21 mmHg. 7. Over 0.1 of corrected visual acuity with an eye for evaluation. 8. If both eyes can be evaluated, an eye with higher intraocular pressure will be chosen for evaluation.
Exclusion criteria
Exclusion criteria: 1. Severe visual field defect (Ex:HFA <-15dB) 2. Any corneal abnormality or other condition preventing reliable applanation tonometry. 3. Presence of any external ocular disease, inflammation or infection of the eye and/or eyelids. 4. History of refractive surgery. 5. Diagnosed with degenerative miopia 6. History of laser trabeculoplasty, filtering surgery, trabeculotomy, or cataract surgery within 6 months. 7. Presence of any hypersensitivity to test drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy: Intraocular Pressure Lowering rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety | — |
Countries
Japan
Contacts
Public ContactKazuhiko Mori, Morio Ueno, Yoko Ikeda
Kyoto Prefectural University of Medicine Department of ophthalmology
Outcome results
None listed